Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia's Path Forward

Benzinga.com  November 15, 2016

Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

Business Wire November 10, 2016

Aurinia Establishes At-The-Market Facility

Business Wire November 9, 2016

Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights

Business Wire November 4, 2016

IIROC Trade Resumption - Aurinia Pharmaceuticals Inc.

Newsfile November 3, 2016

IIROC Trade Resumption - AUP

Canada NewsWire November 3, 2016

IIROC Trading Halt - AUP

Canada NewsWire November 2, 2016

IIROC Trade Halt - Aurinia Pharmaceuticals Inc.

Newsfile November 2, 2016

Aurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting With FDA

Business Wire November 2, 2016

Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings

Business Wire October 24, 2016

Research Reports Coverage on Biotech Stocks -- Merrimack Pharma, Aurinia Pharma, Aegerion Pharma, and TG Therapeutics

PR Newswire October 24, 2016

Aurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on October 18, 2016

Business Wire October 11, 2016

16 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 10, 2016

18 Biggest Mid-Day Losers For Friday

Benzinga.com  October 7, 2016

Mid-Afternoon Market Update: Crude Oil Up 1.5%; Alnylam Pharma Shares Tumble On Revusiran Termination

Benzinga.com  October 6, 2016

Mid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter Shares Slide

Benzinga.com  October 6, 2016

Here's Why Aurinia Pharmaceuticals Soared 35% Today

Benzinga.com  October 6, 2016

Stocks Hitting 52-Week Highs

Benzinga.com  October 6, 2016

Mid-Morning Market Update: Markets Open Lower; Yum! Brands Sales Miss Estimates

Benzinga.com  October 6, 2016

Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis

Business Wire October 6, 2016